Mastocytosis - Clinical findings and diagnosis;Mastozytose - Klinisches bild und diagnostik

Deutsche Medizinische Wochenschrift

Volumn 131, Issue 28-29, 2006, Pages 1616-1621

  Ruëff, Franziska ^a   Dugas Breit, S ^a   Bauer, C ^a   Placzek, M ^a   Przybilla, B ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Mastocytosis; Osteoporosis; Tryptase; Urticaria pigmentosa

Indexed keywords

STEROID;

ANAPHYLAXIS; CLINICAL EXAMINATION; CLINICAL FEATURE; DERMATOLOGY; DISEASE CLASSIFICATION; MALABSORPTION; MASTOCYTOSIS; MUTATION; OSTEOPOROSIS; PATHOGENESIS; PROGNOSIS; REVIEW; URTICARIA PIGMENTOSA; WORLD HEALTH ORGANIZATION;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MASTOCYTOSIS; PROGNOSIS;

EID: 33746839227     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-947809     Document Type: Review

References (48)

1. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004; 103: 3222-3225
2. Bauer C, Ruëff F, Przybilla B. Notfälle in der Allergologie. Hautarzt 2004; 55: 525-532
3. Blunk JA, Schmelz M, Zeck S, Skov P, Likar R, Koppert W. Opioid-induced mast cell activation and vascular responses is not mediated by mu-opioid receptors: an in vivo microdialysis study in human skin. Anesth Analg 2004; 98: 364-370
4. Bucher B, Simic P, Furrer J, Wüthrich B. Mastozytose: eine wichtige Differentialdiagnose bei anaphylaktischer Reaktion auf Hymenopterenstiche. Schweiz Rundsch Med Prax 2000; 89: 411-418
5. Brockow K, Scott LM, Worobec AS, Kirshenbaum A, Akin C, Huber MM, Metcalfe DD. Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: correlation with clinical patterns of disease. Arch Dermatol 2002; 138: 785-790
6. Brockow K, Akin C, Huber M, Metcalfe DD. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol 2003; 48: 508-516
7. Czarnetzki BM, Kolde C, Schoemann A, Urbanitz S, Urbanitz D. Bone marrow findings in adult patients with urticaria pigmentosa. J Am Acad Dermatol 1988; 18: 45-51
8. Delling G, Ritzel H, Werner M. Histologische Charakteristika und Häufigkeit der sekundären Osteoporose bei systemischer Mastozytose. Eine retrospektive Analyse an 158 Fällen. Pathologe 2001; 22: 132-140
9. Dugas-Breit S, Schopf P, Dugas M, Schifft H, Rueff F, Przybilla B. Baseline serum levels of mast cell tryptase are raised in hemodialysis patients and associated with severity of pruritus. J Dtsch Dermatol Ges 2005; 3: 343-347
10. Fearfield LA, Francis N, Henry K, Costello C, Bunker CB. Bone marrow involvement in cutaneous mastocytosis. Br J Dermatol 2001; 144: 561-566
11. Florian S, Krauth MT, Simonitsch-Klupp I, Sperr WR, Fritsche-Polanz R, Sonneck K, Fodinger M, Agis H, Bohm A, Wimazal F, Horny HP, Valent P. Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int Arch Allergy Immunol 2005; 136: 273-280
12. Fricker M, Helbling A, Schwartz L, Müller U. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol 1997; 100: 11-15
13. Golkar L, Bernhard JD. Mastocytosis. Lancet 1997; 349: 1379-1385
14. Hartmann K, Metcalfe DO. Pediatric mastocytosis. Hematol Oncol Clin North Am 2000; 14: 625-640
15. Hidvegi B, Nagy E, Szabo T, Temesvari E, Marschalko M, Karpati S, Horvath A, Gergely P. Correlation between T-cell and mast cell activity in patients with chronic urticaria. Int Arch Allergy Immunol 2003; 132: 177-182
16. Horan RF, Austen KF. Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J Invest Dermatol 1991; 96: 5S-14S
17. Kettelhut BV, Metcalfe DD. Pediatric mastocytosis. Ann Allergy 1994; 73: 197-202
18. Kiszewski AE, Duran-Mckinster C, Orozco-Covarrubias L, Gutierrez-Castrellon P, Ruiz-Maldonado R. Cutaneous mastocytosis in children: a clinical analysis of 71 cases. J Eur Acad Dermatol Venereol 2004; 18: 285-290
19. Kors JW, Van Doormaal JJ, Breukelman H, Van Voorst Vader PC, De Monchy JG. Long-term follow-up of indolent mastocytosis in adults. J Intern Med 1996; 239: 157-164
20. Kränke B, Sturm G, Aberer W. Negative venom skin test results and mastocytosis. J Allergy Clin Immunol 2004; 113: 180-181
21. Lawrence JB, Friedman BS, Travis WD, Chinchilli VM, Metcalfe DD, Gralnick HR. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med 1991; 91: 612-624
22. Ludolph-Hauser D, Ruëff F, Fries C, Schöpf P, Przybilla B. Constitutionally raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet 2001; 357: 361-362
23. Ludolph-Hauser D, Schöpf P, Ruëff F, Przybilla B. Okkulte kutane Mastozytose. Hautarzt 2001; 52: 390-393
24. Marone G, Stellato C, Mostronardi P, Mazzarella B. Mechanisms of activation of human mast cells and basophils by general anesthetic drugs. Ann Fr Anesth Reanim 1993; 12: 116-125
25. Middelkamp Hup MA, Heide R, Tank B, Mulder PG, Oranje AP. Comparison of mastocytosis with onset in children and adults. J Eur Acad Dermatol Venereol 2002; 16: 115-120
26. Möller R, Paul E. Acetylsalicylsäure als Augmentationsfaktor einer Nahrungsmittel-Allergie. Hautarzt 1996; 47: 281-283
27. Müller U, Helbling A, Hunziker T, Wuthrich B, Pecoud A, Gilardi S, Beretta E, Fasel J, Messerli W, Maurer P. Mastocytosis and atopy: a study of 33 patients with urticaria pigmentosa. Allergy 1990; 45: 597-603
28. Oude Elberink JNG, de Monchy JGR, Kors JW, van Doormaal JJ, Dubois AEJ. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 1997; 99: 153-154
29. Pardanani A, Kimlinger TK, Reeder TL, Li CY, Tefferi A. Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder. Br J Haematol 2003; 120: 691-694
30. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, Gilliland DG, Dewald GW, Tefferi A. CHIC2 deletion, a surrogate for FIPIL1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 102: 3093-3096
31. Pardanani A. Systemic mastocytosis: bone marrow pathology, classification, and current therapies. Acta Haematol 2005; 114: 41-51
32. Przybilla B, Müller U, Jarisch R, Ruëff F. Erhöhte basale Serumtryptasekonzentration oder Mastozytose als Risikofaktor der Hymenopterengiftallergie. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie. Allergo J 2004; 3: 440-442
33. Raisz L. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005; 115: 3318-2225
34. Rodermund OE, Klingmuller G, Rohner HG. Interne Befunde bei Mastozytose. Hautarzt 1980; 31: 175-178
35. Rosbotham JL, Malik NM, Syrris P, Jeffery S, Bedlow A, Gharraie S, Murday VA, Holden CA, Carter ND. Lack of c-kit mutation in familial urticaria pigmentosa. Br J Dermatol 1999; 140: 849-852
36. Ruëff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001; 108: 1027-1032
37. Ruëff F, Dugas-Breit S, Bauer C, Schöpf P, Albert K, Marx R, Przybilla B. Diagnose und Therapie der Insektengiftallergie bei Mastozytose. Allergo J 2005; 14: 514-515
38. Ruëff F, Bauer C, Albert K, Przybilla B. Mastocytosis is a stronger risk factor for treatment failure of Hymenoptera venom immunotherapy than elevated baseline serum tryptase. Allergy Clin Immunol Int - J WAO Org 2005(Suppl 117: 69
39. Sagher F, Even-Paz Z. Mastocytosis and the mast cell: Chicago: Year Book Medical Publishers, 1967 (zitiert nach Golkar L, Bernhard JD. Mastocytosis). Lancet 1997; 349: 1379-1385
40. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987; 316: 1622-1626
41. Schwartz LB, Bradford TB, Rouse C, Irani A-M, Rasp G, van der Zwan JK, van der Linden P-WG. Development of a new, more sensitive immunoassy for human tryptase: use in systemic anaphylaxis. J Clin Immunol 1994; 14: 190-204
42. Schwartz LB, Sakai K, Bradford TR, Ren S, Zweimann B, Worobec AS. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest 1995; 96: 2702-2710
43. Siegert SI, Diebold J, Ludolph-Hauser D, Lohrs U. Are gastrointestinal mucosal mast cells increased in patients with systemic mastocytosis? Am J Clin Pathol 2004; 122: 560-565
44. Sotlar K, Horny HP, Simonitsch I, Krokowski M, Aichberger KJ, Mayerhofer M, Printz D, Fritsch G, Valent P. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004; 28: 1319-1325
45. Sperr WR, Stehberger B, Wimazal F, Baghestanian M, Schwartz LB, Kundi M, Semper H, Jordan JH, Chott A, Drach J, Jager U, Geissler K, Greschniok A, Horny HP, Lechner K, Valent P. Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk Lymphoma 2002; 43: 1097-1105
46. Stankovic K, Sarrot-Reynauld F, Puget M, Massot C, Ninet J, Lorcerie B, Dupond JL, Salles G, Durieu I, Vital Durand D, Rousset H. Systemic mastocytosis: predictable factors of poor prognosis present at the onset of the disease. Eur J Intern Med 2005; 16: 387-390
47. Valent P, Akin C, Sperr WR, Mayerhofer M, Fodinger M, Fritsche-Polanz R, Sotlar K, Escribano L, Arock M, Horny HP, Metcalfe DD. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005; 46: 35-48
48. Williams A, Krishna T, Frew A. Systemic mastocytosis. Lancet 2002; 360: 1611